Abstract
Importance Physical activity guidelines are predominantly based on questionnaire-based studies measuring only longer planned physical activity bouts (>10-15 continuous minutes). To date, short intermittent bouts of physical activity that may be beneficial for health (“micropatterns”), have counted very little towards physical activity guidelines (currently 150-300 minutes of moderate or 75-150 minutes of vigorous intensity activity per week).
Objective We examined all-cause and cardiovascular disease (CVD) mortality associations of wearable device-captured activity accumulated through intermittent moderate to vigorous (IMVPA; ≤3 min) and vigorous (IVPA; ≤1 min) intensity bouts, by guideline adherence for a) active adults (eg. doing at least 150 mins/wk of moderate or 75 mins/wk of vigorous intensity physical activity), and b) inactive adults (not meeting the above amounts).
Design Prospective cohort study
Setting UK Biobank
Participants 62,899 adults (mean age 61 years, 55.7% female) with wrist-worn accelerometer data, followed up for an average of 8.0 (SD= 0.9) years
Exposures Intermittent moderate-vigorous (IMVPA; ≤3 min) and vigorous (IVPA; ≤1 min) intensity bouts; stratified by participants meeting and not meeting physical activity guidelines.
Main outcomes and measures All-cause and CVD mortality obtained through linkage with the National Health Service (NHS) Digital of England and Wales or the NHS Central Register and National Records of Scotland. Cox restricted cubic spline regression were used to assess the dose-response associations.
Results There were 1,583 all-cause and 442 CVD deaths among 62,899 adults (mean age 61 years, 55.7% female). Micropatterns accrued IMVPA and IVPA showed linear beneficial dose response associations in both the inactive and active groups. We observed a 1.4 to 2.0-fold lower mortality risk among inactive compared to active adults. For all-cause mortality, a median 4.0 minutes/day of IVPA was associated with a hazard ratio (HR) of 0.40 [0.32, 0.52] in inactive adults and 0.74 [0.58, 0.95] in active adults, compared to not doing any IVPA. For CVD mortality, a median of 13.0 minutes/day of IMVPA was associated with an HR of 0.32 [0.22, 0.51] in inactive adults and 0.53 [0.37, 0.78] in active adults. Analogous patterns of dose-response were present when adherence to guidelines was assessed using questionnaire-based data that only considered continuous activity bouts lasting at least 10 minutes.
Conclusions and relevance Among participants not meeting guidelines, intermittent moderate-vigorous physical activity showed stronger beneficial dose-response association with all-cause and CVD mortality, compared to active adults, highlighting potential health benefits from brief activity bursts for less active adults. Considering such activity patterns are hardly represented in the evidence used to develop current guidelines, our findings support the transition of future guidelines towards wearables-informed evidence.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is funded by an Australian National Health and Medical Research Council Investigator Grant (APP 1194510).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally from the UK Biobank Study
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The manuscript title has been updated
Data Availability
All data produced in the present study are available upon reasonable request to the authors
